Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas and Pfizer announced positive Phase 3 VERITAC-2 trial results for vepdegestrant in ER+/HER2- advanced or metastatic breast cancer patients with ESR1 mutations who progressed after prior CDK4/6 inhibitor and endocrine therapy. Vepdegestrant demonstrated a statistically significant 2.9-month improvement in median progression-free survival compared to fulvestrant, reducing the risk of disease progression or death by 43% in this subgroup; however, the trial did not reach statistical significance for the overall intent-to-treat population. The companies plan to submit a New Drug Application to the FDA in the second half of 2025, positioning vepdegestrant as a potential best-in-class monotherapy for this patient population.

Analysis

Arvinas and Pfizer have reported significant positive results from the Phase 3 VERITAC-2 trial for vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader, in patients with ER+/HER2- advanced or metastatic breast cancer harboring an ESR1 mutation whose disease progressed after prior CDK4/6 inhibitor and endocrine therapy. In this pre-specified subgroup, vepdegestrant demonstrated a statistically significant and clinically meaningful 2.9-month improvement in median progression-free survival (PFS) compared to fulvestrant (5.0 months vs. 2.1 months), translating to a 43% reduction in the risk of disease progression or death (Hazard Ratio=0.57; P<0.001). Notably, vepdegestrant is the first PROTAC evaluated in a Phase 3 trial to show benefit in breast cancer. However, the trial did not achieve statistical significance for PFS improvement in the broader intent-to-treat (ITT) population, where median PFS was 3.7 months for vepdegestrant versus 3.6 months for fulvestrant (HR=0.83; P=0.07). Vepdegestrant was generally well-tolerated, with low rates of gastrointestinal-related adverse events and treatment discontinuations occurring in 2.9% of patients. Secondary endpoints, including clinical benefit rate (42.1% vs. 20.2%) and objective response rate (18.6% vs. 4.0%), also favored vepdegestrant in the ESR1-mutant cohort. Given that ESR1 mutations are found in approximately 40% of second-line patients and drive resistance, these findings, highlighted at ASCO and published in the New England Journal of Medicine, position vepdegestrant as a potentially key treatment for this specific, challenging patient population. Arvinas and Pfizer plan to submit a New Drug Application to the FDA in the second half of 2025, supported by this data and vepdegestrant's Fast Track designation, though overall survival data remains immature.

Key Decisions for Investors

• For Arvinas (ARVN) investors, these results significantly de-risk vepdegestrant and validate its PROTAC platform specifically for the ESR1-mutant breast cancer segment, offering a clear path to potential regulatory approval and commercialization, though the ITT population results and pending overall survival data warrant continued observation.
• Pfizer (PFE) investors can view this as a positive pipeline advancement strengthening its oncology franchise through a co-development agreement that shares costs and potential profits, thereby mitigating individual risk, albeit with a proportionally smaller impact on its overall valuation compared to Arvinas.
• Investors should closely monitor the planned New Drug Application submission in the second half of 2025, subsequent FDA interactions, the maturation of overall survival data from the VERITAC-2 trial, and the competitive landscape for oral ER degraders, particularly focusing on the ESR1-mutant market segment.
• Evaluate the substantial market opportunity for vepdegestrant within the ESR1-mutant patient population, which constitutes approximately 40% of second-line ER+/HER2- breast cancer cases and represents a significant unmet need, while factoring in that current data primarily supports targeted use rather than a broader application in the ITT population.